Scholarlink

<p>POLE or POLD1 deficiency (PPD) leads to an exceptionally high mutation burden and distinct mutational signatures that can inform immunotherapy responses. While some PPD-associated variants have been identified, many remain classified as variants of unknown significance. We analyzed 235,161 tumors across multiple datasets (GENIE, TCGA, and CPC) to develop a comprehensive catalog of PPD driver variants, using an iterative Support Vector Machine algorithm that incorporates both the number of SNVs and PPD-associated mutational signatures. Our iterative approach identified 581 PPD tumors and 65 driver variants, validating many previously reported variants and expanding this list. Thus, we curated the most comprehensive list of PPD drivers up to date. Notably, while the majority of POLE driver variants are located within the exonuclease domain (n = 39), we identified 3 new driver variants outside this domain. Additionally, 7.2% (n = 42) of the PPD samples did not harbor any driver variants, highlighting the need to classify tumors as PPD rather than relying solely on observed driver variants when making treatment decisions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comprehensive characterization of DNA polymerases driver variants using large genomic dataset

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月3日

查看全文
  • Dana Dayan,
  • Hagay Ladany,
  • Fabian Glaser,
  • William D. Foulkes,
  • Yosef E. Maruvka

摘要

POLE or POLD1 deficiency (PPD) leads to an exceptionally high mutation burden and distinct mutational signatures that can inform immunotherapy responses. While some PPD-associated variants have been identified, many remain classified as variants of unknown significance. We analyzed 235,161 tumors across multiple datasets (GENIE, TCGA, and CPC) to develop a comprehensive catalog of PPD driver variants, using an iterative Support Vector Machine algorithm that incorporates both the number of SNVs and PPD-associated mutational signatures. Our iterative approach identified 581 PPD tumors and 65 driver variants, validating many previously reported variants and expanding this list. Thus, we curated the most comprehensive list of PPD drivers up to date. Notably, while the majority of POLE driver variants are located within the exonuclease domain (n = 39), we identified 3 new driver variants outside this domain. Additionally, 7.2% (n = 42) of the PPD samples did not harbor any driver variants, highlighting the need to classify tumors as PPD rather than relying solely on observed driver variants when making treatment decisions.